Pheast Therapeutics to Present Preclinical Data on PHST001, a First-in-class Antibody Targeting CD24, at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting

On October 2, 2026 Pheast Therapeutics, a clinical-stage biotechnology company advancing next-generation targeted therapies for cancer, reported an upcoming poster presentation of preclinical data on PHST001 at the 41st Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting, taking place from November 4-8 in Phoenix, AZ. PHST001 is a first-in-class anti-CD24 macrophage checkpoint inhibitor designed to restore immune recognition in the tumor microenvironment and is currently being evaluated in a Phase 1 clinical trial in patients with solid tumors, including ovarian cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the presentation are as follows:

Title: PHST001, a humanized anti-CD24 hIgG4 antibody, activates macrophages and enhances T cell immune response in preclinical models of solid tumors
Abstract/Poster #: 410
Session Date/Time: Saturday, November 7, 2026, 12:30 p.m. MT

About PHST001

PHST001 is an anti-CD24 macrophage checkpoint inhibitor designed to restore immune recognition in the tumor microenvironment. CD24 is highly expressed across many cancers, where high expression is associated with poor prognosis. Pheast has engineered PHST001 to be a potential best-in-class antibody designed to induce macrophages to phagocytose cancer cells and initiate a powerful immune response. PHST001-101 is an open-label, multicenter Phase 1 study in patients with advanced solid tumors (ClinicalTrials.gov Identifier: NCT06840886) evaluating safety, tolerability, and dose optimization, with secondary objectives assessing pharmacokinetics and preliminary anti-tumor activity. PHST001 received FDA Fast Track Designation for the treatment of ovarian cancer in June 2025.

(Press release, Pheast Therapeutics, OCT 2, 2026, View Source [SID1234671251])